Objective: We aim to describe current clinical practice, the past decade of experience and factors related to improved outcomes for pediatric patients receiving high-frequency oscillatory ventilation. We have also modeled predictive factors that could help stratify mortality risk and guide future high-frequency oscillatory ventilation practice. Design: Multicenter retrospective, observational questionnaire study. Setting: Seven PICUs. Patients: Demographic, disease factor, and ventilatory and outcome data were collected, and 328 patients from 2009 to 2010 were included in this analysis. Interventions: None. Measurement and Main Results: Patients were classified into six cohorts based on underlying diagnosis. We used univariate analysis to identify factors associated with mortality risk and multivariate logistic regression to identify independent predictors of mortality risk. An oxygenation index greater than 35 and immunocompromise exhibited the greatest predictive power (p < 0.0001) for increased mortality risk, and respiratory syncytial virus was associated with lowest mortality risk (p = 0.003). Differences in mortality risk as a function of oxygenation index were highly dependent on primary underlying condition. A trend toward an increase in oscillator amplitude and frequency was observed when compared with historical data. Conclusions: Given the number of centers and subjects included in the database, these findings provide a robust description of current 2661 practice regarding the use of high-frequency oscillatory ventilation for pediatric hypoxic respiratory failure. Patients with severe hypoxic respiratory failure and immunocompromise had the highest mortality risk, and those with respiratory syncytial virus had the lowest. A means of identifying the risk of 30-day mortality for subjects can be obtained by identifying the underlying disease and oxygenation index on conventional ventilation preceding the initiation of high-frequency oscillatory ventilation. (Crit Care Med 2015; 43:2660-2667 
H igh-frequency oscillatory ventilation (HFOV) is a form of mechanical ventilation that has demonstrated benefit in children with moderate and severe acute respiratory distress syndrome (ARDS) (1, 2) . HFOV has become a standard mode of ventilatory support in the PICU (1, 3) . Only two randomized trials of HFOV in pediatric patients have been published (4, 5) . Despite limited clinical trial data, HFOV is being used as a rescue mode of ventilation when conventional lung protective ventilatory modalities have failed (1) .
HFOV uses a constant distending pressure (the mean airway pressure [MAP]) coupled with a sinusoidal flow oscillation, to achieve adequate alveolar ventilation using smaller tidal volumes than delivered during conventional mechanical ventilation (CMV). This allows the use of higher MAPs to aggressively pursue alveolar recruitment while avoiding repetitive opening and collapse of atelectasis-prone lung (atelectrauma). The use of tidal volumes at or less than deadspace reduces the need for high peak airway pressures in the poorly compliant lung and reduces the prevalence of volutrauma and barotrauma. Therefore, HFOV provides lung protective ventilation with lower peak-to-trough pressure amplitudes while simultaneously preventing alveolar collapse.
Biotrauma has also become an important consideration because it may exacerbate lung injury, promote translation of inflammatory mediators, and contribute to the systemic inflammatory response associated with acute lung injury. In several models of lung injury, HFOV has been associated with lower concentrations of inflammatory cytokines than CMV (6, 7) .
Clinical trials have demonstrated that HFOV produces rapid improvement in oxygenating efficiency with minimal hemodynamic side effects (3, 8) . In pediatric patients with acute lung injury and air leak, HFOV was associated with improvement in arterial to alveolar oxygenation (PaO 2 /PAO 2 ) ratio and oxygenation index (OI) (4) . The patients treated with HFOV had a lower prevalence of lung injury, defined by any use of supplemental oxygen at 30 days, than patients managed with CMV. A recently published meta-analysis of eight randomized controlled trials in adults and children suggested that HFOV may decrease mortality risk and has a lower prevalence of treatment failure (8) .
In 2013, the Oscillation in ARDS study group conducted a randomized controlled trial of HFOV when compared with that of CMV and reported that the use of HFOV had no significant effect on 30-day mortality risk in patients with ARDS who required mechanical ventilation (9) . Simultaneously, the Oscillation for Acute Respiratory Distress Syndrome Treated Early study group reported that the early application of HFOV, when compared with a CMV strategy, increases mortality risk (10) . These studies provide insight into adult practices, but it remains unclear how relevant adult studies looking at nonrescue application of HFOV are to pediatric practice (2, 3, 11) .
We have previously reported a multicenter HFOV experience in 10 tertiary care PICUs (1) . That study was able to broadly reflect practices and outcomes in pediatric patients who received HFOV. In the present study, we surveyed three North American and four European centers to describe the evolution of HFOV clinical practice and outcomes in the past 10 years.
MATERIALS AND METHODS
Seven high-volume tertiary PICUs with significant experience using HFOV provided data regarding practice patterns and outcomes with the use of a single HFOV device (model 3100A or 3100B; CareFusion, Yorba Linda, CA). The participating centers were Boston Children's Hospital (Boston, MA), Children's Medical Center of Dallas (Dallas, TX), Queen Paola Children's Hospital (Antwerp, Belgium), University Hospitals of Geneva (Geneva, Switzerland), University Medical Center Utrecht (Utrecht, Netherlands), Universiteit Medical Center (Amsterdam, Netherlands), Hospital for Sick Children (Toronto, ON). The data collection tool was a paper-based detailed case report form for any pediatric patient treated with HFOV during the study period from 2009 to 2010, which was 10 years after the prior study (1) . Patients were identified by chart review; in some institutions, the respiratory care departments kept their own databases. All patients receiving HFOV during the study period were counted. The case report form included information about the etiology of acute lung injury, comorbidities, conventional ventilator management prior to HFOV and after HFOV, arterial blood gas data, ventilator settings on HFOV for the first 72 hours, and patient outcomes. The research ethics committee at each of the participating centers approved this study.
Respiratory therapists, physicians, or nurses at each institution completed the case report forms. Case report forms were collated, and the first and the second authors checked for any missing data points or data that seemed out of physiologic range, which may have been entered by error. In those cases, the primary institution was contacted to confirm data. If there were still missing or unresolved data points, then those patients were excluded from the study. The data were entered into a database for statistical analysis in Microsoft Excel (v14.0.6129.5000; Microsoft, Redmond, WA).
Patients were stratified to one of five distinct categories based upon primary diagnosis and a category for acute treatment failure:
1. History of lung disease (previous history of chronic lung disease before initiation of HFOV A total of 361 case report forms were collected from the collaborating institutions, which represented all of the patients managed with HFOV during the study period. A total of 12 cases were excluded due to missing outcome data, ventilatory data, and diagnosis. In 21 cases involving patients treated with HFOV more than once, a single case report form was generated for the first HFOV run. Therefore, a total of 328 case report forms were included in the analysis.
The centers all had experience with HFOV and the single device used (CareFusion 3100A and 3100B). The center sizes ranged from six beds to 48 beds, with an average total ICU admission rate during the study period of 2,583 patients (range, 550-5723). Table 1 provides a detailed patient description of the 328 patients included in our analysis. All subjects were categorized into one of six predetermined categories based on their primary diagnosis, or acute treatment failure, which was determined from physician documentation in the medical record.
Disease groups were compared using the Mann-Whitney U test for median and interquartile range in patient age, height, weight, conventional ventilation duration and follow-up, and the Pearson chi-square test for gender. Conventional settings immediately preceding HFOV such as positive end-expiratory pressure (PEEP), pH, Fio 2 , PaO 2 , OI, and at initiation of HFOV (such as deltaP, power, frequency, and bias flow) are summarized by means and sd with groups compared by analysis of variance with post hoc Dunnett t tests using no prior lung disease as the reference category (12) . The relationship between deltaP (cm H 2 O) and frequency (Hz) with respect to patient's weight was analyzed using linear and nonlinear regression models with a power function of the general form y = ax b , providing the best fit to the data as judged by R 2 both for the current study and for the Arnold 2000 study (13) . Disease groups were compared in terms of prevalence of 30-day mortality risk using logistic regression. Independent predictors of 30-day mortality risk based on continuous covariates, such as pH and OI at initial HFOV, were modeled using multivariable logistic regression with the backward selection procedure and the likelihood ratio test to assess significance. The probability of mortality risk using maximum likelihood estimation was derived for each disease group based on a range of OI, adjusted for age and gender (14) . Receiver operating characteristic curve analysis based on the Youden J-index was applied to identify the optimal cutoff value of OI at the start of HFOV for assessing mortality risk, and on the basis of this cutoff value and the specific disease group, we constructed a multivariable predictive algorithm (15) . Among survivors, univariate and multivariable logistic regressions were used to determine predictive CMV factors immediately preceding HFOV of the need for respiratory support or supplemental oxygen with the goal of developing a risk stratification model. Power analysis indicated that the sample sizes for the disease groups provided 80% power to detect a 30% difference in OI between each group when compared with patients with no prior lung disease based on the F-test in analysis of variance (version 7.0; nQuery Advisor; Statistical Solutions, Saugus, MA). Statistical analysis was performed using IBM/SPSS Statistics (version 21.0; IBM, Armonk, NY). Two-tailed p values of less than 0.05 were considered statistically significant. Table 1 provides subject demographics for each of the six discrete categories for those patients who were included in the analysis. Comparisons with the referent cohort (no prior lung disease) were done, and statistically significant differences are denoted by values of p less than *0.05 and **0.01. Table 2 shows the CMV settings just prior to the initiation of HFOV. The acute treatment failure group had a statistically significantly higher PaO 2 than the other groups (p < 0.05). The RSV group showed a higher respiratory rate (p < 0.01), lower FIO 2 (p < 0.05), and a higher pH (p < 0.05) prior to initiation of HFOV. Patients with congenital heart disease had a lower PEEP (p < 0.05), higher respiratory rate (p < 0.01), and longer duration of CMV (p < 0.01). The immunocompromised group was on a higher PEEP (p < 0.05). The OI at the time of initiation of HFOV for RSV, immunocompromised patients, and those with no prior lung disease is presented in Figure 1 . In each category, greater than 70% of patients had an OI greater than 16 preceding initiation of HFOV, with the majority (> 60%) having an OI greater than 24. Centers did not consistently report peripheral capillary oxygen saturation (SpO 2 ), so that was not included in the analysis. To assess change in HFOV strategy over time, we examined deltaP by weight and frequency by weight when compared with data reported in a prior publication describing practice in the late 1990s (1) . As shown in Supplemental Figure 1 Data are mean ± sd, except duration of conventional mechanical ventilation, which is median (interquartile range). In the acute treatment failure group, the PaO 2 was elevated. In the respiratory syncytial virus group, RR and pH were significantly higher and Fio 2 was decreased. In the cyanotic heart disease group, RR was significantly higher. In the immunocompromised group, PEEP was significantly higher. HFOV = high-frequency oscillatory ventilation. All values were compared with no prior lung disease group ( a p < 0.05; b p < 0.01).
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December 2015 • Volume 43 • Number 12 pressure amplitudes (deltaP) and higher frequency (Hz) in our cohort when compared with those in the prior data set (1) . Our power regression analyses yielded a statistically significant fit of the model and coefficients of determination: R 2 and p values were R 2 = 0.476 (p < 0.001) and R 2 = 0.289 (p < 0.001) for the deltaP-weight and frequency-weight associations.
Quantification of Mortality Risk
Including all categories, the overall mortality risk in this study was 38.1%. The patients with immunocompromise showed the highest mortality risk. An OI greater than 35 and immunocompromise exhibited the greatest predictive power (p < 0.001) for mortality risk when compared with no prior lung disease. RSV was associated with survival (p = 0.003). Once we separated the patients into their disease groups, we were able to create a model to predict 30-day mortality risk by looking at both disease category and OI at the initiation of HFOV (Fig. 2) .
Multivariable logistic regression analysis confirmed that both OI obtained during CMV immediately preceding HFOV (likelihood ratio = 9.61 on 1 df; p = 0.002) and diagnosis (likelihood ratio test = 18.76 on 4 df; p = 0.001) are significant predictors of 30-day mortality risk. Subgroup analysis revealed a significantly increasing risk of 30-day mortality for higher levels of OI for patients with history of lung disease (p = 0.03), patients with cyanotic heart disease (p = 0.03), and immunocompromised patients (p = 0.04) (Fig. 2) . Patients with RSV (p = 0.16) and those patients with no prior lung disease (p = 0.22) did not show a statistically significant increase in mortality risk with higher OI. Further analysis with adjustment for OI during CMV preceding HFOV initiation confirmed that when compared with patients with no prior lung disease, the risk of mortality was significantly higher in patients with cyanotic heart disease (p = 0.034) and those who were immunocompromised (p < 0.001). Patients with RSV were at a significantly lower risk of 30-day mortality than those with no prior lung disease (p = 0.041) independent of the level of OI. No significant differences were detected between patients with and without a history of lung disease (p = 0.20).
We evaluated whether or not there was a time period within which OI may start to separate survivors from non-survivors. Not surprisingly and as reported by a number of authors, the overall OI in the survivors was lower (1, 5) than in the nonsurvivors. Initially, both survivors and nonsurvivors had improvement in OI, but at approximately 48 hours, the OI increased The bars are color coded by the range of OI, and the percentages above the bars represent the percentage of patients from that disease category with that range of OI. In all categories, greater than 70% of patients had an OI greater than 16 preceding initiation of HFOV, with the majority (> 60%) having an OI greater than 24. RSV = respiratory syncytial virus.
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steadily in nonsurvivors than in survivors (Fig. 3) . This trend was evident for patients with lung disease and patients with no prior lung disease.
Risk of Chronic Lung Disease
We defined chronic lung disease as ongoing need for any respiratory support or supplemental oxygen among survivors at 30 days, regardless of disposition at that time. The two independent multivariate predictors of the need for respiratory support were low pH and high OI on CMV immediately preceding initiation of HFOV. Receiver operating characteristic analysis revealed cutpoints of less than 7.3 for pH and greater than 25 for OI as being significant predictors of requirement of respiratory support for all patients or any use of supplemental oxygen at 30 days following initiation of HFOV. Among all patients who survived and had a pH less than 7.3 and OI greater than 25, there was an 80% probability that they required any respiratory support at 30 days when compared with patients who exhibit pH greater than 7.3 and OI less than 25, in which case the probability is 20%. Univariate analysis indicated diagnosis and the following five CMV variables as predictors of need for respiratory support: decreased pH (p = 0.006), decreased PaO 2 (p = 0.009), decreased P/F ratio (p = 0.003), increased Fio 2 (p = 0.008), and increased OI (p = 0.006).
DISCUSSION
Despite limited clinical trial data, HFOV is used as a rescue mode of ventilatory support in the PICU (2, 3, 11) . A recent analysis of PICU practices by Gupta et al suggested that HFOV might not be effective; however, the conclusions and methods presented in the analysis by Gupta et al (16) have been meet with skepticism (17) (18) (19) .
In the current study, we have described recent HFOV practices, which we feel are representative of the evolution of practice in North America and Western Europe. This study was designed to provide a 10-year follow-up to the original study by Arnold et al (1) . A decade is an appropriate amount of time to watch practice evolve. More recently, some institutions have created their own HFOV guidelines. The ways in which guidelines affect practice is interesting, but not the goal of this article. So we used data prior to these changes as better representation of the evolution of the use of HFOV in pediatric patients. The main findings of this study are that the immunocompromise group had the highest mortality risk and the RSV group the lowest. Eighty percent of patients with RSV were initiated on HFOV with an OI greater than 16 and 61% with OI greater than 24, indicating a rescue strategy versus a primary (nonrescue) HFOV strategy, which likely would have shown HFOV initiation at a lower OI (Fig. 1) . When compared with a decade ago, we observed a trend toward higher Hertz and higher deltaP strategy on HFOV. Finally, the probability of 30-day mortality risk can be estimated by identifying the underlying condition and computing OI on CMV prior to the initiation of HFOV.
Analysis of the CMV settings prior to initiation of HFOV showed predictable trends, including a lower PEEP and longer duration of CMV in the congenital heart disease group. We believe this is reflective of the tendency to limit negative cardiopulmonary interaction by limiting airway opening pressure in ventilated cardiac patients. It is also possible that these patients were transitioned to HFOV to improve alveolar ventilation rather than to enhance oxygenation, which may also explain the lower PEEP prior to HFOV. The immunocompromised patients were managed with higher PEEP, which is likely reflective of the secondary lung injury caused by their disease process. Overall, the RSV group had lower Fio 2 and higher pH at the time of transition to HFOV, showing a possible trend toward using earlier HFOV in this patient population. Although not statistically significant, the RSV group did show a trend toward shorter duration of CMV prior to HFOV. Interestingly, the acute treatment failure group started with a significantly higher PaO 2 , perhaps suggesting that if the primary derangement is not oxygenation, HFOV may not be the ideal modality.
Once HFOV was initiated, the acute treatment failure group was on a higher frequency. From our retrospective analysis, it is difficult to precisely identify factors related to treatment failure in the six who survived. It is possible that they developed adverse hemodynamic effects, hypercarbia or a combination that would discourage the clinician from altering HFOV strategy or persisting with the mode for an extended trial. The six who died during the 3-hour period were likely too severely ill to be rescued by any ventilator modality.
The OSCILLATE study group findings demonstrated that early use of HFOV might increase mortality risk (10) . In Figure 1 , we demonstrate that in representative groups, greater than 70% of patients had an OI greater than 16 preceding initiation of HFOV, with the majority (> 60%) having an OI greater than 24. This implies that in current pediatric practice, HFOV is still being used as a rescue strategy and not as a primary mode of ventilatory support. Therefore, the OSCILLATE data, which focuses on primary application of HFOV in adults, may not be applicable to current pediatric practice.
Our data demonstrate a higher Hertz and higher deltaP strategy than data from the past decade (1) . This change in practice is likely related to evolution of our understanding of the lung protective effects of HFOV. Meyer et al (20) and Liu et al (6) used an animal model to demonstrate less lung injury and reduced levels of inflammatory mediators using a higher Hertz strategy. Hager et al (21) examined factors determining Vt during HFOV in both a test lung model and patients using a hot wire anemometer placed in series with a Sensormedics 3100B high-frequency ventilator. In patients with ARDS, they reported that increasing frequency by 2 Hz was associated with a 23.1% (± 6.3%) reduction in delivered Vt, while that increasing deltaP by 10 cm H 2 O was associated with only a 5.6 (± 4.5%) increase in delivered Vt (18) . This demonstrates that higher Hertz results in lower tidal volumes, and an increase in deltaP does not contribute as significantly to increasing Vt. Our data demonstrate that centers in North America and Western Europe are using higher Hertz, higher deltaP strategies, which may represent an attempt to provide enhanced lung protection with HFOV (1).
In our cohort, an OI greater than 35 and immunocompromise exhibited the greatest predictive power (p < 0.0001) for mortality risk. Furthermore, we were able to determine probability of 30-day mortality risk by disease category and OI at initiation of HFOV. This emphasizes the relevance of underlying disease process in predicting response to HFOV and overall mortality risk. It is clear from our data that certain patient groups treated with HFOV, such as patients with RSV, maintain a low mortality rate.
The strengths of this study are that we have complete HFOV data on all patients included in the analysis. Furthermore, we have included both small and large centers from North America and Western Europe and therefore believe that our data provide a robust description of current practice. The major weakness is that this is a retrospective, questionnaire study. Comparison data and criteria for changes from CMV to HFOV are not available. We also did not collect hemodynamic data. In addition, there are more cases from North America than from Europe. This may potentially skew the study to better represent North American practices.
CONCLUSIONS
The present study provides an update on current practices surrounding application of HFOV in pediatric subjects over the past decade. On the basis of these trends, in this study, we observed that the mortality risk might be linked to disease category rather than the use of HFOV itself. Patients with immunocompromise had the highest mortality risk, and those with RSV had the lowest. HFOV continues to be used as a rescue mode of ventilation in the pediatric population. The regression models we have described, which predict 30-day mortality risk and need for respiratory support, may assist in determining ideal ventilatory modality and overall prognosis.
